These potent systemic actions lead to a reduction in visceral adiposity and dramatically improve systemic metabolic control (Weghuber et al., 2022
That means a supplement patch can be sold without proving it works the company only needs to ensure the product is safe and not adulterated
Patients experiencing hair thinning should be encouraged to discuss their concerns with their GP or prescribing clinician rather than discontinuing treatment abruptly, as the underlying condition being treated (diabetes or obesity) requires ongoing management
Additionally, addressing emotional eating and building a supportive network are essential steps in your journey
Lets take a closer look at retatrutide, what early studies have shown so far, and when it could be available
Key Takeaways Retatrutide targets three hormones (GLP-1, GIP, glucagon), tirzepatide targets two (GLP-1, GIP), and semaglutide targets one (GLP-1) At 68 weeks, retatrutide achieved 28.7% average weight loss, tirzepatide approximately 22%, and semaglutide around 17% on the highest doses Side effects are similar across all three medications, mainly digestive issues like nausea and diarrhoea Retatrutide is not yet approved and won't be available until mid-2026 at the earliest Retatrutide is not yet approved and is not currently available in the UK Tirzepatide (Mounjaro) and semaglutide (Wegovy) are both available now in the UK through NHS or private providers By entering I agree to the Terms and Conditions
